Diabetes · SGLT2 InhibitorRegulatory Approvalcommercialmid-term

Teva's ANDA Submission for Canagliflozin Receives TA Status

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Teva27 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/24/2026, 12:30:35 PM

Assessment confidence: 65% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

Teva's ANDA submission for Canagliflozin with TA status marks a significant competitive entry into the SGLT2 inhibitor market. This could disrupt pricing and market share dynamics, necessitating a strategic response from existing players. Regulatory context from FDA (FDA TA — CANAGLIFLOZIN (ORIG)) supports the near-term read. Assessment grounded in 24 ranked evidence items (10 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of Teva's potential entry on market dynamics and pricing strategies. The strongest clinical anchor is A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) (ClinicalTrials.gov), sponsor/company relevance (merck). In Diabetes · SGLT2 Inhibitor, 6 regulatory and 7 competitive items passed relevance filtering for Teva.

Competitive Pressure

The most relevant competitive pressure comes from [Ad hoc announcement pursuant to Art. (Roche) — sponsor/company relevance (roche). Secondary pressure from [Ad hoc announcement pursuant to Art.. This submission indicates Teva's entry into the SGLT2 inhibitor market, potentially increasing competition against established players.

Regulatory Outlook

Regulatory risk is concentrated around FDA TA — CANAGLIFLOZIN (ORIG) (FDA). Entity match (teva); Regulatory pathway relevance (nda). The standard review status indicates a typical timeline for approval, but the TA status highlights the importance of monitoring the FDA's decisions closely.

Key Risks

Elevated medium regulatory exposure for Teva could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Teva's entry may lead to increased competition, potentially affecting revenue and market positioning for established SGLT2 inhibitors.
Diabetes · SGLT2 Inhibitor / DPP-4 Inhibitor · Regulatory Approval · This approval strengthens AstraZeneca's position in the diabetes market, particularly against competitors offering similar combination therapies.
Upside for Teva may improve if An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy (ClinicalTrials.gov) delivers favorable follow-through.
CDK4/6 inhibitors (CDK4/6i) represent the standard treatment for HR+/HER2- ABC. The study assessed the efficacy and safety profiles of CDK4/6i from first-line (1 L) to third-line (3 L) in patients with HR+/HER2- ABC from high-altitude versus low-altitude regions.
Portfolio teams should assess the impact of Teva's potential entry on market dynamics and pricing strategies.

What Would Change This Assessment

This becomes more urgent if Monitor the review progress and any upcoming decisions from the FDA regarding this ANDA submission.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA TA — CANAGLIFLOZIN (ORIG)
FDAhigh relevance
Entity match (teva); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — CANAGLIFLOZIN (ORIG)
FDAhigh relevance
Entity match (canagliflozin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — CANAGLIFLOZIN (ORIG)
FDAhigh relevance
Entity match (canagliflozin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ELTROMBOPAG OLAMINE (ORIG)
FDAhigh relevance
Entity match (teva); Regulatory pathway relevance (nda)
FDA document
View source
Innovative Science and Technology Approaches for New Drugs (ISTAND) Program Submission Process
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA’s Drug Registration and Listing Workshop: Compliance, Regulatory and Submission Updates - 09/29/2026
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Merck)
FDA document
View source
An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Modified Mini-PCNL Versus Standard PCNL for Complex Kidney Stones
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Relationship Between Clinical Status and Nerve Conduction Test Findings in Patients With Unilateral Hemiplegia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Management of Abdominal Post-surgical Scar With Ozoaqua Versus Standard Care
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Menstrual Status, Anesthetic Consumption, and PONV
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

[Ad hoc announcement pursuant to Art.
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
[Ad hoc announcement pursuant to Art.
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
[Ad hoc announcement pursuant to Art.
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
Novartishigh relevance
Sponsor/company relevance (Novartis)
FDA document
View source
FDA Approves Supplemental Application for QTERN (Dapagliflozin/Saxagliptin)
Humanexa Signalshigh relevance
Sponsor/company relevance (AstraZeneca)
FDA Approves ANDA for Tofacitinib Citrate by Sun Pharma
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Approval for Tofacitinib Citrate (ANDA217298)
Humanexa Signalsmedium relevance
Moderate corpus alignment

Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effectiveness and safety of brentuximab vedotin-containing regimen versus standard chemotherapy in relapsed or refractory Hodgkin lymphoma: a multicenter cohort study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy and drug survival after transitioning to IL-17 inhibitors in patients with psoriasis who did not respond to IL-23 inhibitors: analysis from the BIOREP registry.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Preclinical characterization of HEC116094, an oral inhibitor of the influenza A virus polymerase PB2 subunit.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Teva
Canagliflozin
established players

Commercial impact

medium

Teva's entry may lead to increased competition, potentially affecting revenue and market positioning for established SGLT2 inhibitors.

Regulatory impact

medium

The standard review status indicates a typical timeline for approval, but the TA status highlights the importance of monitoring the FDA's decisions closely.

What to watch

Monitor the review progress and any upcoming decisions from the FDA regarding this ANDA submission.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.